BeOne Medicines (ONC) Goldman Sachs 45th Annual Global Healthcare Conference summary

R&D Model and Operational Strategy

• Adopted a CRO-free, in-house clinical trial model, enabling faster, lower-cost, and higher-quality studies globally across six continents.

• Internal delivery model reduced costs by about 30% and improved protocol deviation detection by nearly 100 days.

• Built a 3,000-person development organization and one of the largest oncology research teams worldwide.

• Model allows rapid, high-quality decision-making for phase transitions and supports a robust global pipeline.

• In-house model is difficult to replicate now due to resource constraints and required expertise.

Research, Pipeline, and Innovation

• Maintains a large preclinical research group with 1,200 scientists, focusing on novel and underexplored targets in lung, GI, breast, and hematologic cancers.

• 2024 marks the first year with over 10 new molecular entities (NMEs) entering the clinic, emphasizing both quality and quantity.

• Stopped 20 preclinical programs last year that did not meet target characteristics, streamlining the pipeline.

• Over 60 potential medicines in the pipeline, including innovative assets in hematology and solid tumors, with 24,000+ patients enrolled in 130+ trials worldwide.

• Recognized as a top global oncology company for phase 3 trial completions and number of molecules advanced into the clinic between 2017 and 2023.

ADCs and Manufacturing

• Entered the ADC space with proprietary technology: site-specific conjugation, hydrophilic linker, and a potent exatecan derivative warhead.

• Targeting novel and underexplored antigens, including first FGFR2b ADC and multi-specific ADCs planned for 2025.

• Built manufacturing facilities in China and the U.S. to ensure supply chain control, efficiency, and cost optimization.

• In-house manufacturing supports rapid program advancement and aligns with access and affordability goals.

• Significant investments in global manufacturing support portfolio growth and global launches.